# Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

> **NCT03504982** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 74 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Vericiguat (BAY1021189)
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03504982
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-17
- **Primary completion:** 2018-11-29
- **Final completion:** 2019-02-26
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2020-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03504982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03504982, "Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03504982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*